Do Youn Oh (Do-Youn Oh)

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 25

Top Topics

Tyrosine Kinase

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature reviews. Clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jeesun Yoon, Do Youn Oh
HER2-targeted therapies beyond breast cancer - an update. Nature reviews. Clinical oncology (2024)
Ana Oaknin, Jung-Yun Lee, Vicky Makker, Do Youn Oh, Susana Banerjee, Antonio Gonzáles Martin, Kyung Hae Jung, Iwona Lugowska, Luis Manso, Aránzazu Manzano Fernández, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Soham Puvvada, Ann Smith, Funda Meric-Bernstam
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in therapy (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, an Irreversible FGFR1-4 Inhibitor: Pooled Safety analysis of 469 patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jeesun Yoon, Do Youn Oh
HER2-targeted therapies beyond breast cancer - an update. Nature reviews. Clinical oncology 21 (9) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Petros D Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal, James J Harding, Elizabeth C Dees, Rastislav Bahleda, Nilofer S Azad, Asha Karippot, Razelle Kurzrock, Josep Tabernero, Juha Kononen, Matthew Chau Hsien Ng, Rutika Mehta, Nataliya V Uboha, Frédéric Bigot, Valentina Boni, Samantha E Bowyer, Valeriy Breder, Andres Cervantes, Nancy Chan, James M Cleary, Mallika Dhawan, Rikke Helene Løvendahl Eefsen, James Ewing, Donna M Graham, Tormod Kyrre Guren, Jin Won Kim, Krassimir Koynov, Do Youn Oh, Rebecca A Redman, Chia-Jui Yen, David B Spetzler, Marie-Claude Roubaudi-Fraschini, Valérie Nicolas, Rafik Ait-Sarkouh, Claudio Zanna, Abdallah Ennaji, Anna Pokorska-Bocci, Keith T Flaherty
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors. Cancer research communications (2024)
Jeesun Yoon, Do Youn Oh
HER2-targeted therapies beyond breast cancer - an update. Nature reviews. Clinical oncology (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Funda Meric-Bernstam, Antoine Hollebecque, Junji Furuse, Do Youn Oh, John A Bridgewater, Masashi Shimura, Bailey Anderson, Nanae Hangai, Volker Wacheck, Lipika Goyal
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Do Youn Oh, Alain Algazi, Jaume Capdevila, Federico Longo, Wilson Miller, Jerry Tan Chun Bing, Carlos Eduardo Bonilla, Hyun Cheol Chung, Tormod K Guren, Chia-Chi Lin, Daniel Motola-Kuba, Manisha Shah, Julien Hadoux, Lili Yao, Fan Jin, Kevin Norwood, Loïc Lebellec
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer (2023)
Do Youn Oh, Alain Algazi, Jaume Capdevila, Federico Longo, Wilson Miller, Jerry Tan Chun Bing, Carlos Eduardo Bonilla, Hyun Cheol Chung, Tormod K Guren, Chia-Chi Lin, Daniel Motola-Kuba, Manisha Shah, Julien Hadoux, Lili Yao, Fan Jin, Kevin Norwood, Loïc Lebellec
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer 129 (8) (2023)
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Paige Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lionel Aurelien Kankeu Fonkoua, Bradley J Monk, Danny Nguyen, Do Youn Oh, Alicia F C Okines, David M O'Malley, Paula Pohlmann, Martin Reck, Sang Joon Shin, Kazuki Sudo, Shunji Takahashi, Cedric Van Marcke, Evan Y Yu, Roman Groisberg, Jorge Ramos, Sherry Tan, Thomas Eldridge Stinchcombe, Tanios S Bekaii-Saab
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Funda Meric-Bernstam, Vicky Makker, Ana Oaknin, Do Youn Oh, Susana Banerjee, Antonio Gonzáles Martin, Kyung Hae Jung, Iwona Ługowska, Luis Manso Sanchez, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham Puvvada, Norah Shire, Jung-Yun Lee
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Do Youn Oh, Alain Algazi, Jaume Capdevila, Federico Longo, Wilson Miller, Jerry Tan Chun Bing, Carlos Eduardo Bonilla, Hyun Cheol Chung, Tormod K Guren, Chia-Chi Lin, Daniel Motola-Kuba, Manisha Shah, Julien Hadoux, Lili Yao, Fan Jin, Kevin Norwood, Loïc Lebellec
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer 129 (8) (2023)
Margaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, Jordan M Winter, Do Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D Lopez, Tanios S Bekaii-Saab, Andrew H Ko, Armando Santoro, Joon Oh Park, Marcus S Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan D Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V Biankin, Michele Reni, null null
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Hedy Lee Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do Youn Oh, Anke C Reinacher-Schick, Giampaolo Tortora, Hana Algül, Eileen M O'Reilly, Sonal Bordia, David McGuinness, Karen Y Cui, Gershon Y Locker, Talia Golan
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (34) (2022)
Kyoung-Seok Oh, Ah-Rong Nam, Ju-Hee Bang, Hye-Rim Seo, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do Youn Oh
A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene 41 (32) (2022)
Yoo Jin Choi, Yoonhyeong Byun, Jae-Seung Kang, Hyeong Seok Kim, Youngmin Han, Hyeong Seok Kim, Wooil Kwon, Do Youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji-Kon Ryu, Yong-Tae Kim, Kyoung-Bun Lee, Haeryoung Kim, Eui Kyu Chie, Jin-Young Jang
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut and liver 15 (3) (2021)
Seung Jun Han, Hee Won Jung, Do Youn Oh, Jae Hyun Lee, Sung Do Moon, Sunhye Lee, Jung Hwan Yoon
Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. Journal of Korean medical science 35 (18) (2020)
Shalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, Saeed Sadeghi, Ivan Borbath, Lipika Goyal, Allen Cohn, Angela Lamarca, Do Youn Oh, Teresa Macarulla, Rachna T Shroff, Michael F Howland, Ai Li, Terry Cho, Amit Pande, Milind M Javle
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future oncology (London, England) 16 (30) (2020)
Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Hak Jae Kim, Hong-Gyun Wu, Il Han Kim, Do Youn Oh, Se-Hoon Lee, Dong Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Sung W Ha
Impact of multimodality approach for patients with leptomeningeal metastases from solid tumors. Journal of Korean medical science 29 (8) (2014)